Subcommittee for Dose Reconstruction Reviews (SDRR), Advisory Board on Radiation and Worker Health (ABRWH or the Advisory Board), National Institute for Occupational Safety and Health (NIOSH), 3802-3803 [2016-01223]
Download as PDF
<![CDATA[
3802
Federal Register / Vol. 81, No. 14 / Friday, January 22, 2016 / Notices
that are considered in acting on the
notices are set forth in paragraph 7 of
the Act (12 U.S.C. 1817(j)(7)).
The notices are available for
immediate inspection at the Federal
Reserve Bank indicated. The notices
also will be available for inspection at
the offices of the Board of Governors.
Interested persons may express their
views in writing to the Reserve Bank
indicated for that notice or to the offices
of the Board of Governors. Comments
must be received not later than February
8, 2016.
A. Federal Reserve Bank of Kansas
City (Dennis Denney, Assistant Vice
President) 1 Memorial Drive, Kansas
City, Missouri 64198–0001:
1. Theodore E. Dimmitt, Fremont,
Nebraska, individually, and Phyllis J.
Monke, Fremont, Nebraska; Thomas L.
Monke, Arlington, Nebraska; Cynthia J.
Lingren, Eryaman, Ankara, Turkey; Jean
M. Katt, Herman, Nebraska; as members
of the Monke Family Group, to
collectively acquire voting shares of
Arlington State Banc Holding Company,
and thereby indirectly acquire voting
shares of Two Rivers State Bank, both in
Blair, Nebraska.
Board of Governors of the Federal Reserve
System, January 19, 2016.
Michael J. Lewandowski,
Associate Secretary of the Board.
[FR Doc. 2016–01250 Filed 1–21–16; 8:45 am]
BILLING CODE 6210–01–P
FEDERAL RESERVE SYSTEM
mstockstill on DSK4VPTVN1PROD with NOTICES
Change in Bank Control Notices;
Acquisitions of Shares of a Bank or
Bank Holding Company
The notificants listed below have
applied under the Change in Bank
Control Act (12 U.S.C. 1817(j)) and
§ 225.41 of the Board’s Regulation Y (12
CFR 225.41) to acquire shares of a bank
or bank holding company. The factors
that are considered in acting on the
notices are set forth in paragraph 7 of
the Act (12 U.S.C. 1817(j)(7)).
The notices are available for
immediate inspection at the Federal
Reserve Bank indicated. The notices
also will be available for inspection at
the offices of the Board of Governors.
Interested persons may express their
views in writing to the Reserve Bank
indicated for that notice or to the offices
of the Board of Governors. Comments
must be received not later than February
4, 2016.
A. Federal Reserve Bank of St. Louis
(Yvonne Sparks, Community
Development Officer) P.O. Box 442, St.
Louis, Missouri 63166–2034:
VerDate Sep<11>2014
16:59 Jan 21, 2016
Jkt 238001
1. Notice by Michael D. Yingling, Mt.
Sterling, Illinois; to acquire additional
voting shares of Mt. Sterling Bancorp,
Inc., Mt. Sterling, Illinois and thereby
acquire shares of Farmers State Bank &
Trust Company, Mount Sterling Illinois.
Board of Governors of the Federal Reserve
System, January 15, 2016.
Michael J. Lewandowski,
Associate Secretary of the Board.
[FR Doc. 2016–01191 Filed 1–21–16; 8:45 am]
BILLING CODE 6210–01–P
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The applications will also be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than February 18,
2016.
A. Federal Reserve Bank of Atlanta
(Chapelle Davis, Assistant Vice
President) 1000 Peachtree Street NE.,
Atlanta, Georgia 30309. Comments can
also be sent electronically to
Applications.Comments@atl.frb.org:
1. Charter Financial Corporation,
West Point, Georgia; to become a bank
holding company by merging with CBS
Financial Corporation, and thereby
indirectly acquire Community Bank of
the South, both in Smyrna, Georgia.
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
Board of Governors of the Federal Reserve
System, January 19, 2016.
Michael J. Lewandowski,
Associate Secretary of the Board.
[FR Doc. 2016–01249 Filed 1–21–16; 8:45 am]
BILLING CODE 6210–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Subcommittee for Dose
Reconstruction Reviews (SDRR),
Advisory Board on Radiation and
Worker Health (ABRWH or the
Advisory Board), National Institute for
Occupational Safety and Health
(NIOSH)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting for the
aforementioned subcommittee:
Time and Date: 10:30 a.m.–5:00 p.m.,
EST, February 10, 2016.
Place: Audio Conference Call via FTS
Conferencing.
Status: Open to the public, but
without a public comment period. The
public is welcome to submit written
comments in advance of the meeting, to
the contact person below. Written
comments received in advance of the
meeting will be included in the official
record of the meeting. The public is also
welcome to listen to the meeting by
joining the teleconference at the USA
toll-free, dial-in number at 1–866–659–
0537 and the pass code is 9933701.
Background: The Advisory Board was
established under the Energy Employees
Occupational Illness Compensation
Program Act of 2000 to advise the
President on a variety of policy and
technical functions required to
implement and effectively manage the
new compensation program. Key
functions of the Advisory Board include
providing advice on the development of
probability of causation guidelines that
have been promulgated by the
Department of Health and Human
Services (HHS) as a final rule; advice on
methods of dose reconstruction, which
have also been promulgated by HHS as
a final rule; advice on the scientific
validity and quality of dose estimation
and reconstruction efforts being
performed for purposes of the
compensation program; and advice on
petitions to add classes of workers to the
Special Exposure Cohort (SEC).
E:\FR\FM\22JAN1.SGM
22JAN1
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 81, No. 14 / Friday, January 22, 2016 / Notices
In December 2000, the President
delegated responsibility for funding,
staffing, and operating the Advisory
Board to HHS, which subsequently
delegated this authority to CDC. NIOSH
implements this responsibility for CDC.
The charter was issued on August 3,
2001, renewed at appropriate intervals,
and will expire on August 3, 2017.
Purpose: The Advisory Board is
charged with (a) providing advice to the
Secretary, HHS, on the development of
guidelines under Executive Order
13179; (b) providing advice to the
Secretary, HHS, on the scientific
validity and quality of dose
reconstruction efforts performed for this
program; and (c) upon request by the
Secretary, HHS, advise the Secretary on
whether there is a class of employees at
any Department of Energy facility who
were exposed to radiation but for whom
it is not feasible to estimate their
radiation dose, and on whether there is
reasonable likelihood that such
radiation doses may have endangered
the health of members of this class. The
Subcommittee for Dose Reconstruction
Reviews was established to aid the
Advisory Board in carrying out its duty
to advise the Secretary, HHS, on dose
reconstruction.
Matters for Discussion: The agenda for
the Subcommittee meeting includes the
following dose reconstruction program
quality management and assurance
activities: Current findings from NIOSH
dose reconstruction blind reviews; dose
reconstruction cases under review from
Sets 14–18, including the Oak Ridge
sites (Y–12, K–25, Oak Ridge National
Laboratory, and Savannah River Site;
preparation of the Advisory Board’s
next report to the Secretary, HHS,
summarizing the results of completed
dose reconstruction reviews.
The agenda is subject to change as
priorities dictate.
Contact Person for More Information:
Theodore Katz, Designated Federal
Officer, NIOSH, CDC, 1600 Clifton Road
NE., Mailstop E–20, Atlanta, Georgia
30333, Telephone (513) 533–6800, Toll
Free 1(800) CDC–INFO, Email ocas@
cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
VerDate Sep<11>2014
16:59 Jan 21, 2016
Jkt 238001
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2016–01223 Filed 1–21–16; 8:45 am]
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2015–D–5105]
Postmarket Management of
Cybersecurity in Medical Devices;
Draft Guidance for Industry and Food
and Drug Administration Staff;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA) is announcing the
availability of a draft guidance entitled
‘‘Postmarket Management of
Cybersecurity in Medical Devices.’’ This
draft guidance informs industry and
FDA staff of the Agency’s
recommendations for identifying,
addressing, and monitoring
cybersecurity vulnerabilities and
exploits for postmarket management of
medical devices. This draft guidance is
neither final nor is it in effect at this
time.
SUMMARY:
Although you can comment on
any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency
considers your comment of this draft
guidance before it begins work on the
final version of the guidance, submit
either electronic or written comments
on the draft guidance by April 21, 2016.
ADDRESSES: You may submit comments
as follows:
DATES:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
3803
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2015–D–5105 for ‘‘Postmarket
Management of Cybersecurity in
Medical Devices.’’ Received comments
will be placed in the docket and, except
for those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on https://
www.regulations.gov. Submit both
copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
E:\FR\FM\22JAN1.SGM
22JAN1
]]>Agencies
[Federal Register Volume 81, Number 14 (Friday, January 22, 2016)]
[Notices]
[Pages 3802-3803]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-01223]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Subcommittee for Dose Reconstruction Reviews (SDRR), Advisory
Board on Radiation and Worker Health (ABRWH or the Advisory Board),
National Institute for Occupational Safety and Health (NIOSH)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC), announces the following meeting for the
aforementioned subcommittee:
Time and Date: 10:30 a.m.-5:00 p.m., EST, February 10, 2016.
Place: Audio Conference Call via FTS Conferencing.
Status: Open to the public, but without a public comment period.
The public is welcome to submit written comments in advance of the
meeting, to the contact person below. Written comments received in
advance of the meeting will be included in the official record of the
meeting. The public is also welcome to listen to the meeting by joining
the teleconference at the USA toll-free, dial-in number at 1-866-659-
0537 and the pass code is 9933701.
Background: The Advisory Board was established under the Energy
Employees Occupational Illness Compensation Program Act of 2000 to
advise the President on a variety of policy and technical functions
required to implement and effectively manage the new compensation
program. Key functions of the Advisory Board include providing advice
on the development of probability of causation guidelines that have
been promulgated by the Department of Health and Human Services (HHS)
as a final rule; advice on methods of dose reconstruction, which have
also been promulgated by HHS as a final rule; advice on the scientific
validity and quality of dose estimation and reconstruction efforts
being performed for purposes of the compensation program; and advice on
petitions to add classes of workers to the Special Exposure Cohort
(SEC).
[[Page 3803]]
In December 2000, the President delegated responsibility for
funding, staffing, and operating the Advisory Board to HHS, which
subsequently delegated this authority to CDC. NIOSH implements this
responsibility for CDC. The charter was issued on August 3, 2001,
renewed at appropriate intervals, and will expire on August 3, 2017.
Purpose: The Advisory Board is charged with (a) providing advice to
the Secretary, HHS, on the development of guidelines under Executive
Order 13179; (b) providing advice to the Secretary, HHS, on the
scientific validity and quality of dose reconstruction efforts
performed for this program; and (c) upon request by the Secretary, HHS,
advise the Secretary on whether there is a class of employees at any
Department of Energy facility who were exposed to radiation but for
whom it is not feasible to estimate their radiation dose, and on
whether there is reasonable likelihood that such radiation doses may
have endangered the health of members of this class. The Subcommittee
for Dose Reconstruction Reviews was established to aid the Advisory
Board in carrying out its duty to advise the Secretary, HHS, on dose
reconstruction.
Matters for Discussion: The agenda for the Subcommittee meeting
includes the following dose reconstruction program quality management
and assurance activities: Current findings from NIOSH dose
reconstruction blind reviews; dose reconstruction cases under review
from Sets 14-18, including the Oak Ridge sites (Y-12, K-25, Oak Ridge
National Laboratory, and Savannah River Site; preparation of the
Advisory Board's next report to the Secretary, HHS, summarizing the
results of completed dose reconstruction reviews.
The agenda is subject to change as priorities dictate.
Contact Person for More Information: Theodore Katz, Designated
Federal Officer, NIOSH, CDC, 1600 Clifton Road NE., Mailstop E-20,
Atlanta, Georgia 30333, Telephone (513) 533-6800, Toll Free 1(800) CDC-
INFO, Email ocas@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2016-01223 Filed 1-21-16; 8:45 am]
BILLING CODE 4163-19-P
